Molecule2Market are a team of experienced clinical research professionals working with clients to achieve their research goals in Australia, Asia-Pacific region, Europe and North America. We are dedicated to advancing the contribution to the research and development of innovative medical treatments.
A privately owned Australian CRO (Clinical Research Organisation), we provide
contract services to the pharmaceutical and biotechnology industries looking to perform clinical research in the region including Asia-Pacific. Our USA business team works with local and international clients across all facets of clinical research in multiple therapeutic areas.
Combining the strength of our expertise and extensive experience (our directors' have over 70 years' collective experience), we provide high quality services across all phases of clinical research in a broad range of therapeutic areas.
Company Details
- Employees
- 19
- Founded
- -
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- molecule2market.com.au
Molecule2market Questions
Molecule2Market's website is molecule2market.com.au
Molecule2Market's LinkedIn profile is https://au.linkedin.com/company/molecule2market
Molecule2Market has
19 employees.
View email and phone details for 19
employees at Molecule2Market.
Molecule2Market's industry is
Pharmaceutical Manufacturing
Molecule2Market's top competitors are
Akesa,
Cmax Clinical Research,
Accelagen Pty Ltd,
Alithia Life Sciences,
Purecdm,
Southern Star Research,
Beigene,
Avance Clinical,
Beyond Drug Development,
Molecule To Market.
Molecule2Market's categories are Pharmaceutical Manufacturing
Molecule2Market's founding year is 2012
